vasopressin - early initiation
Phase 3Small molecule
vasopressin - early initiation is one of 36 small molecule programs targeting Sepsis. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
100 competitors in Sepsis
#DrugCompanyPhaseTrials
1Gleevec
NovartisPhase 2
Antibiotics
MMelinta Therapeutics, Inc.
Phase 3
N-Acetylcysteine (NAC) Treatment
TThe First Affiliated Hospital of Soochow University
Phase 3
Decadron
AAspen Global Incorporated
Phase 2
Nafamostat Mesylate
EEnsysce Biosciences
Phase 3
vasopressin - early initiation
TThe Cleveland Clinic
Phase 3
Hydrocortisone Administration
UUniversity of Virginia
Phase 3
Simdax
Orion Corporation, Orion PharmaPreclinical
Zyvox
PfizerPreclinical
Zemplar
AbbViePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- TThe Cleveland Clinic